Clinical Trials Open To Enrollment

Currently Enrolling Clinical Trials for Patients with Memory Loss

  • An 18-month trial investigating an infusion-based treatment which may target amyloid plaque in the brain. We have one program for people with mild cognitive impairment that lasts 78 weeks. There is a similar treatment program that lasts 100 weeks for patients with mild cognitive impairment and mild Alzheimer’s disease.
  • A 96-week trial investigating an infusion-based treatment which may target tau protein in the brain. This study is for patients with mild cognitive impairment and mild Alzheimer’s disease.
  • An 18-month trial investigating an oral medication, which may inhibit a particular enzyme known to be part of the amyloid production process. This study is for individuals with mild Alzheimer’s disease.
  • A 6-month study investigating an oral medication which may increase signaling of neurons in the brain. Subjects must be on 10mg donepezil and either 20mg or 28mg (XR) of memantine to participate in this program. This study is for patients with mild to moderate Alzheimer’s disease.

Currently Enrolling Clinical Trials for Patients without Memory Loss

  • A 3 ½-year prevention study in which participants may receive an amyloid-targeting infusion treatment. This study is for individuals 65-85 years old who are concerned about developing Alzheimer’s disease but currently have no memory problems.
  • A 4 ½-year prevention study in which participants may receive an amyloid-targeting oral medication. This study is for individuals 65-85 years old (or 60-64 with a parent or sibling with Alzheimer’s) who are concerned about developing the disease but currently have no memory problems.

We always have new trials just around the corner! Please check back with us for updates.

For more information about our programs, please contact Jill Smith, MA, CCRC at (813) 974-1294 or jsmith10@health.usf.edu.